AR087094A1 - Formulaciones que estabilizan proteinas - Google Patents

Formulaciones que estabilizan proteinas

Info

Publication number
AR087094A1
AR087094A1 ARP120102467A ARP120102467A AR087094A1 AR 087094 A1 AR087094 A1 AR 087094A1 AR P120102467 A ARP120102467 A AR P120102467A AR P120102467 A ARP120102467 A AR P120102467A AR 087094 A1 AR087094 A1 AR 087094A1
Authority
AR
Argentina
Prior art keywords
formulations
stabilize proteins
buffer
phosphate
therapeutic protein
Prior art date
Application number
ARP120102467A
Other languages
English (en)
Original Assignee
Gtc Biotherapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Gtc Biotherapeutics Inc filed Critical Gtc Biotherapeutics Inc
Publication of AR087094A1 publication Critical patent/AR087094A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/55—Protease inhibitors
    • A61K38/57—Protease inhibitors from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Inorganic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Dermatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

En un aspecto, la presente proporciona formulaciones que estabilizan proteínas, en donde las formulaciones comprenden un búfer. En algunas formas de realización, el búfer comprende mono-hidrógeno-fosfato de potasio y di-hidrógeno-fosfato de potasio, o el búfer comprende mono-hidrógeno-fosfato de sodio y di-hidrógeno-fosfato de sodio. En algunas formas de realización, la proteína es una proteína terapéutica. En algunas formas de realización, la proteína terapéutica es antitrombina.
ARP120102467A 2011-07-07 2012-07-06 Formulaciones que estabilizan proteinas AR087094A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201161505354P 2011-07-07 2011-07-07

Publications (1)

Publication Number Publication Date
AR087094A1 true AR087094A1 (es) 2014-02-12

Family

ID=47437713

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP120102467A AR087094A1 (es) 2011-07-07 2012-07-06 Formulaciones que estabilizan proteinas

Country Status (10)

Country Link
US (1) US20140242182A1 (es)
EP (1) EP2729164A4 (es)
JP (1) JP6178311B2 (es)
KR (1) KR20140054026A (es)
CN (1) CN103945862A (es)
AR (1) AR087094A1 (es)
AU (1) AU2012278836B2 (es)
BR (1) BR112014000217A2 (es)
CA (1) CA2840876A1 (es)
WO (1) WO2013006766A2 (es)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN112076330B (zh) 2010-12-30 2023-06-02 法国化学与生物科技实验室 作为病原体灭活剂的二元醇
AU2013296240B2 (en) 2012-08-03 2018-05-17 Lfb Usa, Inc. The use of antithrombin in extracorporeal membrane oxygenation
CN105263319A (zh) 2013-02-13 2016-01-20 法国化学与生物科技实验室 具有经修饰的糖基化的蛋白及其生产方法
BR112015019341A2 (pt) 2013-02-13 2017-08-22 Lab Francais Du Fractionnement Anticorpo anti-tnf-alfa, composição que compreende o anticorpo, método para produzir uma população de anticorpos, células epiteliais da glândula mamária, mamífero não humano transgênico, e, composição de anticorpo anti-tnf monoclonal
CA2916566A1 (fr) 2013-07-05 2015-01-08 Laboratoire Francais Du Fractionnement Et Des Biotechnologies Matrice de chromatographie d'affinite
AU2018314767B2 (en) * 2017-08-08 2024-03-21 Csl Behring Ag Hemopexin formulations
CN117904091A (zh) * 2024-01-18 2024-04-19 武汉市长立生物技术有限责任公司 一种凝血酶稳定剂以及一种凝血酶时间测定试剂

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH03215430A (ja) * 1990-01-19 1991-09-20 Kita Kiyoshi 関節腔抗凝固剤
JPH0236128A (ja) * 1988-07-25 1990-02-06 Kiyoshi Kita 眼内注射剤
US5135523A (en) * 1988-12-13 1992-08-04 Alza Corporation Delivery system for administering agent to ruminants and swine
US5057318A (en) * 1988-12-13 1991-10-15 Alza Corporation Delivery system for beneficial agent over a broad range of rates
JP3801196B2 (ja) * 1993-03-09 2006-07-26 ジェンザイム・コーポレイション 乳からの対象化合物の単離
JP3822383B2 (ja) * 1993-12-17 2006-09-20 持田製薬株式会社 可溶性トロンボモジュリン含有組成物
US6268487B1 (en) * 1996-05-13 2001-07-31 Genzyme Transgenics Corporation Purification of biologically active peptides from milk
US6365185B1 (en) * 1998-03-26 2002-04-02 University Of Cincinnati Self-destructing, controlled release peroral drug delivery system
JP2000290196A (ja) * 1999-03-31 2000-10-17 Welfide Corp 血圧低下抑制剤
US6448024B1 (en) * 2000-10-03 2002-09-10 Roche Diagnostics Corporation Method, reagent, cartridge, and device for determining fibrinogen
WO2004026427A2 (en) * 2002-09-17 2004-04-01 Gtc Biotherapeutics, Inc. Isolation of immunoglobulin molecules that lack inter-heavy chain disulfide bonds
FR2901796A1 (fr) * 2006-05-31 2007-12-07 Lab Francais Du Fractionnement Procede d'extraction d'une ou de plusieurs proteines presentes dans du lait
GB0700523D0 (en) * 2007-01-11 2007-02-21 Insense Ltd The Stabilisation Of Proteins
PT2473528E (pt) * 2009-09-03 2015-03-04 Ablynx Nv Formulações estáveis de polipéptidos e seus usos

Also Published As

Publication number Publication date
US20140242182A1 (en) 2014-08-28
CN103945862A (zh) 2014-07-23
BR112014000217A2 (pt) 2017-02-07
KR20140054026A (ko) 2014-05-08
AU2012278836B2 (en) 2016-03-10
AU2012278836A1 (en) 2013-05-02
EP2729164A4 (en) 2015-05-06
JP6178311B2 (ja) 2017-08-09
CA2840876A1 (en) 2013-01-10
WO2013006766A3 (en) 2014-05-08
EP2729164A2 (en) 2014-05-14
JP2014520820A (ja) 2014-08-25
WO2013006766A2 (en) 2013-01-10

Similar Documents

Publication Publication Date Title
AR087094A1 (es) Formulaciones que estabilizan proteinas
CY1124024T1 (el) Νεες ctla4-ig ανοσοπροσκολλητινες
CY1124307T1 (el) Φαρμακευτικη συνθεση, μεθοδοι θεραπειας και χρησεις αυτων
CR20190350A (es) INHIBIDORES DE TGFß1 ISOFORMA-ESPECÍFICOS CONTEXTO-PERMISIVOS Y USO DE LOS MISMOS
CL2013003090A1 (es) Polipeptido que comprende una primera secuencia de aminoacidos que comprende a su vez al menos un dominio variable individual de inmunoglobulina que se enlaza especificamente a il-17f, il17-a/f, pero no a il-17a, y una segunda secuencia de aminoacidos que comprende a su vez al menos un dominio variable individual de inmunoglobulina que se enlaza especificamente a il-17a, il-17f y il17-a/f; composicion farmaceutica que lo comprende; y su uso.
ECSP13012384A (es) Composición acuosa que contiene bromhexina
BR112018075140A2 (pt) composição na forma de uma solução aquosa injetável, e, formulação de dose única a um ph de 7 a 7,8
AR087745A1 (es) Composiciones y metodos que comprenden una variante de enzima lipolitica
ECSP088440A (es) Imidazopirazinas como inhibidores de proteinquinasa
CR20110091A (es) Anticuerpos neutralizantes de citomegalovirus humano y uso de los mismos
CL2013003214A1 (es) Formulacion estable que comprende al menos un anticuerpo monoclonal que se une especificamente a pcsk9, un tampon, un surfactante y al menos un estabilizador; y su uso para tratar o prevenir enfermedades relacionadas con el colesterol.
BR112013017080A2 (pt) Anticorpo ou fragmento funcional do mesmo que se liga a forma ativa de calicreína do plasma humano, composiçao farmacêutica e método de detecçao de calicreína do plasma em um paciente
CR10528A (es) Proceso para producir poxvirus y composiciones de poxvirus
GT201200276A (es) Combinaciones de compuestos activos
CR20140318A (es) Composiciones intranasales de dexmedetomidina y métodos de uso de ellas
BR112013020767A2 (pt) composições compreendendo ácido peróxi alfa-cetocarboxílico e métodos para a produção e o uso do mesmo
CR20170425A (es) Nuevas proteínas específicas para pioverdina y pioquelina
AR082422A1 (es) Composicion detergente liquida
UY34527A (es) ?composiciones, métodos y kits para la preparación de proteínas recombinantes sialiladas?.
CU23795A3 (es) Formulaciones líquidas de anticuerpo antirrábico
PE20160012A1 (es) Tratamiento de enfermedades miopaticas y neurogenerativas por agregacion de proteina mediante administracion parenteral
RS54875B1 (sr) Liofilizovane formulacije fgf-18
PE20141683A1 (es) Anticuerpos monoclonales especificos para el antigeno m2-1 del virus respiratorio sincicial (vrs)
CO2017007316A2 (es) Formulación farmacéutica
CY1118967T1 (el) Φαρμακευτικες συνθεσεις υψηλης δοσης βιοτινης

Legal Events

Date Code Title Description
FB Suspension of granting procedure